Clinical trial
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 2b, Multicenter, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study
NCT03861936 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 2b, Multicenter, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study
- Lead sponsor
- Allergan
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 16, 2019
- Completion date
- July 2, 2020
- Enrollment
- 150 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
masseter muscle prominence